- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00602589
A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects
An Open-label, Randomized, 3-way Crossover Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects
Studieoversikt
Status
Forhold
Detaljert beskrivelse
In this single-dose study conducted at at single center, 3 oral formulations of levofloxacin (tablet, suspension, and solution) were assessed for their bioequivalence in healthy men and women aged 18 to 55 years old. Subjects were assigned different treatments based on chance; both the researcher and the study participant knew the treatment being administered. The study consisted of a screening period, 3 open-label treatment periods separated by washout periods of at least 4 days between doses, and a post-treatment period. Subjects received a single dose of all 3 study formulations, administered as a single dose of each formulation on Day 1 of each treatment period. Blood samples were collected on Days 1, 2, and 3 of each treatment period immediately before dosing and at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 10, 14, 24, 30, 36, and 48 hours after dosing for measurement of levofloxacin concentration. Subjects were admitted to the study site prior to dosing and remained through the 48-hour measurements on Day 3. The post-treatment period included physical examination and clinical laboratory testing to ensure subject safety before being discharged from the study. Safety evaluations, including adverse event monitoring, standard clinical laboratory evaluations (hematology, serum chemistry, and urinalysis), vital sign monitoring, and physical examinations, were monitored throughout the study.
Two cohorts of 36 subjects each were enrolled in the study. The first cohort received a single dose of study drug and completed Period 1; the study was then stopped and reinitiated. Subjects from the first cohort completed early termination procedures; their data were included in safety analyses, however, no blood samples for levofloxacin concentrations were analyzed or included in pharmacokinetic analysis. Thirty-four subjects in the second cohort completed all study procedures. Levofloxacin oral suspension (125 mg/5 mL), levofloxacin oral solution (125 mg/5 mL), and levofloxacin tablet (500 mg) administered on Day 1 of each treatment period.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Men and women
- Aged 18 to 55 years
- BMI between 18 and 30 kg/m2
- No prescription or over-the-counter medications for previous 14 days
- Negative tests for drug and alcohol abuse, HIV, hepatitis B and hepatitis C
- and Healthy based on medical history, physical examination, 12-lead electrocardiograms, toxicology, antigen, and antibody screens, and clinical laboratory evaluations
Exclusion Criteria:
- Allergic reaction to quinolones
- Clinically significant ECG or clinical laboratory abnormalities
- Creatinine clearance <=80 mL/min
- Acute illness within 7 days
- Nicotine use within 1 year
- Receipt of experimental drug or device within 60 days
- Pregnant or breastfeeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Assessment of the bioequivalence of the oral suspension formulation, the oral solution formulation, and the marketed tablet formulation of levofloxacin, on Days 1, 2, and 3, using the marketed tablet as the reference.
|
Sekundære resultatmål
Resultatmål |
---|
Assessment of the bioequivalence of the oral suspension and solution formulations, on Days 1, 2, and 3, using the suspension formulation as the reference.
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Enzymhemmere
- Antineoplastiske midler
- Topoisomerase II-hemmere
- Topoisomerasehemmere
- Antibakterielle midler
- Cytokrom P-450 enzymhemmere
- Cytokrom P-450 CYP1A2-hemmere
- Anti-infeksjonsmidler, urinveier
- Nyremidler
- Levofloxacin
- Ofloksacin
Andre studie-ID-numre
- CR011395
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sunn
-
Universidade do PortoFundação para a Ciência e a TecnologiaRekrutteringHealthy People-programmerPortugal
-
VA Office of Research and DevelopmentFullført
-
Universidad Católica del MauleFullført
-
University of MiamiJames and Esther King Biomedical Research ProgramAvsluttetHealthy Lifetime Ikke-røykereForente stater
-
Fundació Institut de Recerca de l'Hospital de la...FullførtHealthy People-programmerSpania
-
University of LeicesterNational Institute for Health Research, United KingdomFullførtPasienter med hjertesvikt og bevart ejeksjonsfraksjon - HFpEF | Pasienter med hjertesvikt med redusert ejeksjonsfraksjon - HFrEF | Healthy Controls Group - alders- og kjønnsmatchet
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvsluttetParkinsons sykdom | Healthy Controls Group - alders- og kjønnsmatchetFrankrike
Kliniske studier på Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations
-
University of RochesterFullførtKronisk rhinosinusittForente stater
-
PfizerFullførtCommunity-ervervet lungebetennelse (CAP)Forente stater, Canada, Tyskland, Hellas, Spania
-
Achaogen, Inc.FullførtAkutt pyelonefritt | Komplisert urinveisinfeksjon
-
Mansoura UniversityUkjentSepsis | Infeksjon | Antibiotika | Perkutan nefrolitotomiEgypt
-
Damascus HospitalHar ikke rekruttert ennåHelicobacter pylori-infeksjonDen syriske arabiske republikk
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University... og andre samarbeidspartnereAktiv, ikke rekrutterendeTuberkulose | Multiresistent tuberkulose | Rifampicin-resistent tuberkulose | Utstrakt legemiddelresistent tuberkulose | Pre-XDR-TBSør-Afrika
-
BayerFullførtLungebetennelseBelgia, Tyskland, Spania, Hellas, Frankrike, Nederland, Chile, Mexico, Polen, Sør-Afrika, Storbritannia, Argentina, Colombia, Israel, Litauen, Peru, Portugal, Sverige
-
University of LouisvilleOsteo Science FoundationHar ikke rekruttert ennåOsteomyelitt av kjevenForente stater
-
Damascus HospitalTilbaketrukketHelicobacter Pylori gastrointestinal tract infeksjonDen syriske arabiske republikk
-
Sheba Medical CenterFullført